The Cancer Center at Cold Spring Harbor Laboratory (CSHL) is a basic research center devoted to the understanding of fundamental biology of human cancer. A principal focus of the research at the Center is to understand the molecular mechanisms that govern cell growth and cell division and how these processes are altered in human tumor cells. This cellular based research focuses mainly on key biological processes, such as gene expression, DMA replication and chromosome segregation during the cell division cycle, RNA processing, cell morphology and cell signaling mechanisms. Intertwined with the research on these fundamental cellular processes is research on the regulatory machineries that coordinate cell growth, cell cycle progression, differentiation and cell death. Increasingly, we have integrated the genetics of human cancer, both familial and sporadic, into this program of basic research, as well as increasing our emphasis on creating and using animal models of human cancer. Together, these approaches are beginning to link cancer genetics to cancer therapy. Finally, we have established a powerful informatics capability that will benefit the analysis of large databases, including those that store sequence information and those more connected to clinical databases. The Cancer Center is organized into three research Programs (Gene Expression, Cancer Genetics and Cell Biology) and eleven Shared Research Resources. Each of the research programs has a strong basic) cancer research focus, but there is increasing research that focuses on clinically important issues such as cancer genetics and cancer therapy. A notable characteristic of the research at the CSHL Cancer Center is the high degree of interactions between the individual research groups. This includes extensive interactions between research groups within programs and in different programs. The Shared Resources provide specialized, state-of-the art equipment and techniques that are available to all Cancer Center Members. These are continually updated and revised as technologies and needs change. This cohesive yet flexible organization has enabled Center investigators to perform research at the highest level, and scientific progress during the last funding period has been substantial.
| Tiriac, Hervé; Belleau, Pascal; Engle, Dannielle D et al. (2018) Organoid Profiling Identifies Common Responders to Chemotherapy in Pancreatic Cancer. Cancer Discov 8:1112-1129 |
| Forcier, Talitha L; Ayaz, Andalus; Gill, Manraj S et al. (2018) Measuring cis-regulatory energetics in living cells using allelic manifolds. Elife 7: |
| Naguib, Adam; Mathew, Grinu; Reczek, Colleen R et al. (2018) Mitochondrial Complex I Inhibitors Expose a Vulnerability for Selective Killing of Pten-Null Cells. Cell Rep 23:58-67 |
| Aberle, M R; Burkhart, R A; Tiriac, H et al. (2018) Patient-derived organoid models help define personalized management of gastrointestinal cancer. Br J Surg 105:e48-e60 |
| Bhagwat, Anand S; Lu, Bin; Vakoc, Christopher R (2018) Enhancer dysfunction in leukemia. Blood 131:1795-1804 |
| Khan, Jalal A; Maki, Robert G; Ravi, Vinod (2018) Pathologic Angiogenesis of Malignant Vascular Sarcomas: Implications for Treatment. J Clin Oncol 36:194-201 |
| Chen, Wei-Chia; Tareen, Ammar; Kinney, Justin B (2018) Density Estimation on Small Data Sets. Phys Rev Lett 121:160605 |
| Cheng, Derek; Tuveson, David (2018) Kras in Organoids. Cold Spring Harb Perspect Med 8: |
| Albrengues, Jean; Shields, Mario A; Ng, David et al. (2018) Neutrophil extracellular traps produced during inflammation awaken dormant cancer cells in mice. Science 361: |
| Cook, Natalie; Basu, Bristi; Smith, Donna-Michelle et al. (2018) A phase I trial of the ?-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma. Br J Cancer 118:793-801 |
Showing the most recent 10 out of 380 publications
